P106 Maintenance treatment with granulocyte/monocyte adsorption in patients with inflammatory bowel disease and an initial response to treatment: a Swedish long-term prospective registry study
A. Lindberg1, 2, S. Lindgren3, M. Lördal4, S. Nilsson5, H. Svensson6, P. Karlen*1
1Department of Clinical Science, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden, Stockholm, Sweden, 2Karolinska Institutet, Danderyds hospital, Department of Clinical Science, Stockholm, Sweden, 3Department of Gastroenterology, University Hospital Skane, Sweden, Malmö, Sweden, 4Department of Medicine, Division of Gastroenterology and Hepathology at Karolinska Institutet, Huddinge, Sweden, Stockholm, Sweden, 5Department of Medicine, Kristianstad Hospital, Kristianstad, Sweden,, Kristianstad, Sweden, 6Departments of Internal Medicine, Vrinnevi Hospital, Norrköping, Sweden, Norrköping, Sweden
Inflammatory bowel diseases (IBD) are chronic, with different character and intermittent or more rarely continuous inflammatory activity. The activity ranges from mild to severe. The response to treatment varies and the choice of treatment is still partly arbitrary. Some patients represent a particular problem because of lack of response or intolerance to conventional treatment. Data are lacking on results from maintenance treatment with granulocyte/monocyte adsorption (GMA) in patients with an initial response to treatment.
In the study, 136 patients, 54 with ulcerative colitis (UC), 81 with Crohn´s disease (CD), and 1 with indeterminate colitis (IC), were included in a registry covering the majority of patients treated with GMA in Sweden. The disease activity was mainly mild or moderate. Of them, 49 IBD patients initially achieving clinical response 3 months after a GMA course received maintenance treatment with GMA. The GMA maintenance treatments were scheduled with 1 of the following: 1 session monthly, every second month, every third month, and every fourth month, according to relapse rate and disease severity. Included patients were followed every third month for 12 months after induction GMA treatment. Monitoring includes symptoms (short health scale), activity indices (HBI and SCCAI), and faecal calprotectin.
Overall, burden of symptoms, activity indices, and faecal calprotectin levels remained at the same low level throughout the maintenance treatment period.
Maintenance treatment with GMA is effective in patients with an initial good response.